ONVO — Organovo Holdings Share Price
0.000.00%
Last trade - 00:00- $10.14m
- $4.85m
- $0.37m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.64 | ||
| Price to Tang. Book | 1.64 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 41.91 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -275.3% | ||
| Return on Equity | -134.07% | ||
| Operating Margin | -8169.01% | ||
Financial Summary
| Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 3.09 | 2.2 | n/a | 1.5 | 0.37 | 75 | 444 | -39.6% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Organovo Holdings, Inc. is a biotechnology company that focuses on building high fidelity, three-dimensional (3D) tissues that recapitulate various aspects of human disease. The Company uses these models to identify gene targets responsible for driving the disease and intends to initiate drug discovery programs around these validated targets. It is initially focusing on the intestine and has ongoing 3D tissue development efforts in ulcerative colitis (UC) and Crohns disease (CD). The Company uses its technology to build functional 3D human tissues that mimic various aspects of native human tissue composition, architecture, function, and disease. Its NovoGen Bioprinters are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells. Its NovoGen Bioprinters can also dispense pure hydrogel formulations, provided the physical properties of the hydrogel are compatible with the dispensing parameters. Its 3D human tissue platform is multifaceted.
Directors
- Keith Murphy CHM (49)
- Thomas Hess PRE (57)
- Jeffrey Miner CSO (52)
- Thomas Jurgensen GCN (64)
- Douglas Cohen IND (50)
- David Gobel IND (68)
- Alison Milhous IND (42)
- Adam Stern IND (57)
- Last Annual
- March 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- January 27th, 2012
- Public Since
- August 2nd, 2013
- No. of Shareholders
- 81
- No. of Employees
- 15
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 10,040,074
- Address
- Suite 110, 6275 Nancy Ridge Drive, SAN DIEGO, 92121
- Web
- https://organovo.com/
- Phone
- +1 8585509994
- Auditors
- Mayer Hoffman & McCann P.C.
Upcoming Events for ONVO
Q1 2024 Organovo Holdings Inc Earnings Release
Similar to ONVO
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Organovo Holdings share price?
As of Today at 19:16 UTC, shares in Organovo Holdings are trading at $1.01. This share price information is delayed by 15 minutes.
How has the Organovo Holdings share price performed this year?
Shares in Organovo Holdings last closed at $1.01 and the price had moved by -54.5% over the past 365 days. In terms of relative price strength the Organovo Holdings share price has underperformed the S&P500 Index by -63.25% over the past year.
What are the analyst and broker recommendations for Organovo Holdings?
The overall consensus recommendation for Organovo Holdings is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Organovo Holdings dividend yield?
Organovo Holdings does not currently pay a dividend.
Does Organovo Holdings pay a dividend?
Organovo Holdings does not currently pay a dividend.
When does Organovo Holdings next pay dividends?
Organovo Holdings does not currently pay a dividend.
How do I buy Organovo Holdings shares?
To buy shares in Organovo Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Organovo Holdings?
As of the previous close price of $1.01, shares in Organovo Holdings had a market capitalisation of $10.14m.
Where are Organovo Holdings shares listed?
Here are the trading details for Organovo Holdings:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ONVO
What kind of share is Organovo Holdings?
Based on an overall assessment of its quality, value and momentum Organovo Holdings is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Organovo Holdings share price forecast for 2024?
The analyst consensus target price for shares in Organovo Holdings is $8.55. That is 746.45% above the last closing price of $1.01.
Analysts covering Organovo Holdings currently have a consensus Earnings Per Share (EPS) forecast of -$1.74 for the next financial year.
What is the trend in the Organovo Holdings share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Organovo Holdings. Over the past six months, its share price has underperformed the S&P500 Index by -29.9%.
As of the last closing price of $1.01, shares in Organovo Holdings were trading -18.98% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Organovo Holdings PE Ratio?
The Organovo Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Organovo Holdings?
Organovo Holdings' management team is headed by:
- Keith Murphy - CHM
- Thomas Hess - PRE
- Jeffrey Miner - CSO
- Thomas Jurgensen - GCN
- Douglas Cohen - IND
- David Gobel - IND
- Alison Milhous - IND
- Adam Stern - IND